AZNAstraZenecaRunning, no new patients
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Metastatic Triple Negative Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 273 (final count)
- Started
- Mar 7, 2018
- Main results expected
- Nov 13, 2020
- Fully finished
- Oct 9, 2026
- Results posted
- Mar 22, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival Per Stratum (BICR)
Measured over: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Progression-free Survival Per Stratum (Sensitivity Analysis)
Measured over: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03330847 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC